← Leaderboards
Kavita Yang Sarin
Stanford University
$886,696
Attributed
$886,696
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $173.6K · FY2011–22$200K$150K$100K$50K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$886,696 · 2
By mechanism
K23$867,780 · 1
F32$18,916 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- James K Chen$23,002,603
- Anthony E Oro$25,372,453
- Paul A Khavari$40,653,927
- Todd W Ridky$5,236,268
- Mark A Krasnow$16,695,034
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsBaseMalignant NeoplasmsSignal TransductionGrowthFutureImmuneLaboratoriesTumorTumorigenesisIn VitroCancer CellBasal Cell CancerCancer Cell GrowthBiopsy SpecimenBiopsyAftercareData ModelingCheckpoint TherapyBioinformaticsBench To BedsideClinical InvestigationClinical TrialsCd8b1 Gene
Grant awards (6)
Repurposing systemic therapies to improve clinical outcomes in advanced basal cell cancer$173,556
K23 · FY2022 · CA · contact PI
Repurposing systemic therapies to improve clinical outcomes in advanced basal cell cancer$173,556
K23 · FY2021 · CA · contact PI
Repurposing systemic therapies to improve clinical outcomes in advanced basal cell cancer$173,556
K23 · FY2020 · CA · contact PI
Repurposing systemic therapies to improve clinical outcomes in advanced basal cell cancer$173,556
K23 · FY2019 · CA · contact PI
Repurposing systemic therapies to improve clinical outcomes in advanced basal cell cancer$173,556
K23 · FY2018 · CA · contact PI
CHARACTERIZING THE ROLE OF IQGAP1 IN ERK MAPK-DRIVEN EPIDERMAL NEOPLASIA$18,916
F32 · FY2011 · AR · contact PI